SOPHiA GENETICS (NASDAQ:SOPH) Coverage Initiated by Analysts at HC Wainwright

Equities researchers at HC Wainwright started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 104.43% from the company’s previous close.

A number of other analysts have also issued reports on SOPH. BTIG Research reiterated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $9.00.

SOPHiA GENETICS Stock Performance

Shares of NASDAQ SOPH opened at $5.87 on Monday. SOPHiA GENETICS has a twelve month low of $2.92 and a twelve month high of $6.30. The company has a current ratio of 2.06, a quick ratio of 1.90 and a debt-to-equity ratio of 1.05. The stock has a fifty day simple moving average of $5.23 and a 200-day simple moving average of $5.02. The stock has a market capitalization of $492.43 million, a PE ratio of -11.29 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million.

Insiders Place Their Bets

In other news, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the transaction, the insider directly owned 614,887 shares of the company’s stock, valued at approximately $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 6,944 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44. Following the completion of the sale, the chief technology officer directly owned 197,456 shares in the company, valued at approximately $1,087,982.56. This trade represents a 3.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 176,711 shares of company stock worth $959,913. Corporate insiders own 4.88% of the company’s stock.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently modified their holdings of the company. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at $50,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the third quarter valued at $49,000. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the 4th quarter worth about $49,000. Quadrature Capital Ltd acquired a new position in shares of SOPHiA GENETICS during the 4th quarter worth about $54,000. Finally, XTX Topco Ltd purchased a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.